LV12274A - 4-(5-Metil-3-fenilizoksazol-4-il) benzosulfonamida kristaliska forma - Google Patents

4-(5-Metil-3-fenilizoksazol-4-il) benzosulfonamida kristaliska forma

Info

Publication number
LV12274A
LV12274A LV990040A LV990040A LV12274A LV 12274 A LV12274 A LV 12274A LV 990040 A LV990040 A LV 990040A LV 990040 A LV990040 A LV 990040A LV 12274 A LV12274 A LV 12274A
Authority
LV
Latvia
Prior art keywords
benzosulfonamide
phenylisoxazol
methyl
crystalline form
crystalline
Prior art date
Application number
LV990040A
Other languages
English (en)
Other versions
LV12274B (lv
Inventor
John J Talley
John R Medich
Kathleen T Mclaughlin
Henry T Gaud
Edward E Yonan
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of LV12274A publication Critical patent/LV12274A/lv
Publication of LV12274B publication Critical patent/LV12274B/lv

Links

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/40—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs
    • H01L23/4006—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs with bolts or screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/42—Fillings or auxiliary members in containers or encapsulations selected or arranged to facilitate heating or cooling
    • H01L23/427—Cooling by change of state, e.g. use of heat pipes
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Power Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Computer Hardware Design (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
LVP-99-40A 1996-08-14 1999-03-05 4-(5-metil-3-fenilizoksazol-4-il)benzosulfonamīda kristāliskā forma LV12274B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2437896P 1996-08-14 1996-08-14
PCT/US1997/015126 WO1998006708A1 (en) 1996-08-14 1997-08-12 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide

Publications (2)

Publication Number Publication Date
LV12274A true LV12274A (lv) 1999-05-20
LV12274B LV12274B (lv) 1999-09-20

Family

ID=21820280

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-40A LV12274B (lv) 1996-08-14 1999-03-05 4-(5-metil-3-fenilizoksazol-4-il)benzosulfonamīda kristāliskā forma

Country Status (39)

Country Link
US (2) US6441014B2 (lv)
EP (2) EP0920422B1 (lv)
JP (2) JP3631763B2 (lv)
KR (1) KR100383148B1 (lv)
CN (1) CN1205193C (lv)
AP (1) AP1055A (lv)
AR (1) AR009244A1 (lv)
AT (1) ATE228117T1 (lv)
AU (1) AU722072B2 (lv)
BG (1) BG64259B1 (lv)
BR (1) BR9711151A (lv)
CA (1) CA2264104A1 (lv)
CZ (1) CZ297679B6 (lv)
DE (1) DE69717281T2 (lv)
DK (1) DK0920422T3 (lv)
EA (2) EA003754B1 (lv)
EE (1) EE04237B1 (lv)
ES (1) ES2188971T3 (lv)
GE (1) GEP20022636B (lv)
HK (1) HK1023125A1 (lv)
HU (1) HUP0400923A3 (lv)
IL (2) IL161224A0 (lv)
IS (1) IS1989B (lv)
LT (1) LT4551B (lv)
LV (1) LV12274B (lv)
NO (1) NO312461B1 (lv)
NZ (1) NZ334132A (lv)
OA (1) OA11298A (lv)
PL (1) PL191313B1 (lv)
PT (1) PT920422E (lv)
RO (1) RO120771B1 (lv)
RS (1) RS49671B (lv)
SI (1) SI9720059B (lv)
SK (1) SK283558B6 (lv)
TR (1) TR199900298T2 (lv)
TW (1) TW527350B (lv)
UA (1) UA52684C2 (lv)
WO (1) WO1998006708A1 (lv)
ZA (1) ZA977314B (lv)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191313B1 (pl) * 1996-08-14 2006-04-28 Searle & Co Postać krystaliczna 4-[5-metylo-3-fenyloizoksazol-4-ilo] benzenosulfonamidu, sposób jej otrzymywania, zawierająca ją kompozycja farmaceutyczna i zastosowania
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
EP1102755B1 (en) * 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
AU1398899A (en) * 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
CA2364127A1 (en) * 1999-03-01 2000-09-08 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and a selective cox-2 inhibitor drug
ES2234651T3 (es) * 1999-08-20 2005-07-01 Ortho-Mcneil Pharmaceutical, Inc. Composicion que comprende una materia de tramadol y un farmaco anticonvulsivo.
CA2381895A1 (en) * 1999-08-27 2001-03-08 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
CA2455050C (en) * 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
US20070072921A1 (en) * 2002-07-26 2007-03-29 Talley John J Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
AU2003238668A1 (en) 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
PL1745791T3 (pl) 2003-05-07 2013-11-29 Osteologix As Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu
US20050182113A1 (en) * 2003-12-30 2005-08-18 Venkataraman Sundaram Method for preparing diaryl-substituted isoxazole compounds
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib
WO2005120499A1 (en) * 2004-06-10 2005-12-22 Chandiran Thakashinamoorthy Form a of valdecoxib suitable for pharmaceutical formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ATE368639T1 (de) * 2004-06-28 2007-08-15 Gruenenthal Gmbh Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
CA2609185A1 (en) 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
EP2026790A2 (en) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
MX2011000090A (es) 2008-06-23 2011-03-02 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida.
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103172583A (zh) * 2013-03-07 2013-06-26 深圳市资福药业有限公司 一种制备帕瑞昔布的方法
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
CN114441666B (zh) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
AU699593B2 (en) * 1995-02-13 1998-12-10 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
PL191313B1 (pl) * 1996-08-14 2006-04-28 Searle & Co Postać krystaliczna 4-[5-metylo-3-fenyloizoksazol-4-ilo] benzenosulfonamidu, sposób jej otrzymywania, zawierająca ją kompozycja farmaceutyczna i zastosowania
AU2003238668A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib

Also Published As

Publication number Publication date
HUP0400923A3 (en) 2007-11-28
US20010003752A1 (en) 2001-06-14
OA11298A (en) 2003-10-22
AP1055A (en) 2002-04-04
CZ297679B6 (cs) 2007-03-07
EP0920422A1 (en) 1999-06-09
LT4551B (lt) 1999-10-25
TR199900298T2 (xx) 1999-05-21
RS49671B (sr) 2007-11-15
LT99024A (en) 1999-07-26
IL128255A0 (en) 1999-11-30
AP9901458A0 (en) 1999-03-31
US20030004200A1 (en) 2003-01-02
EP1283203A1 (en) 2003-02-12
EA199900200A1 (ru) 1999-06-24
WO1998006708A1 (en) 1998-02-19
GEP20022636B (en) 2002-02-25
JP2000506542A (ja) 2000-05-30
IL161224A0 (en) 2004-09-27
BR9711151A (pt) 1999-08-17
SK13699A3 (en) 1999-07-12
YU7499A (sh) 2000-03-21
HK1023125A1 (en) 2000-09-01
NO312461B1 (no) 2002-05-13
DE69717281D1 (de) 2003-01-02
SI9720059A (sl) 1999-12-31
PL331607A1 (en) 1999-08-02
RO120771B1 (ro) 2006-07-28
BG64259B1 (bg) 2004-07-30
EP0920422B1 (en) 2002-11-20
JP3631763B2 (ja) 2005-03-23
CZ33499A3 (cs) 1999-06-16
AU722072B2 (en) 2000-07-20
DK0920422T3 (da) 2003-03-17
KR100383148B1 (ko) 2003-05-09
ATE228117T1 (de) 2002-12-15
US6441014B2 (en) 2002-08-27
IS4961A (is) 1999-01-29
SK283558B6 (sk) 2003-09-11
EA001472B1 (ru) 2001-04-23
DE69717281T2 (de) 2003-09-04
NO990541D0 (no) 1999-02-05
PT920422E (pt) 2003-03-31
EA003754B1 (ru) 2003-08-28
EE04237B1 (et) 2004-02-16
TW527350B (en) 2003-04-11
AR009244A1 (es) 2000-04-12
UA52684C2 (uk) 2003-01-15
CA2264104A1 (en) 1998-02-19
KR20000029994A (ko) 2000-05-25
ES2188971T3 (es) 2003-07-01
ZA977314B (en) 1998-08-14
BG103155A (en) 1999-11-30
NZ334132A (en) 2000-06-23
JP2005015497A (ja) 2005-01-20
AU4093697A (en) 1998-03-06
IL128255A (en) 2004-06-20
HUP0400923A2 (hu) 2004-08-30
NO990541L (no) 1999-02-05
CN1205193C (zh) 2005-06-08
SI9720059B (sl) 2011-11-30
EA200000891A1 (ru) 2001-02-26
IS1989B (is) 2005-02-15
EE9900053A (et) 1999-08-16
PL191313B1 (pl) 2006-04-28
LV12274B (lv) 1999-09-20
CN1233243A (zh) 1999-10-27
US7135489B2 (en) 2006-11-14

Similar Documents

Publication Publication Date Title
LV12274A (lv) 4-(5-Metil-3-fenilizoksazol-4-il) benzosulfonamida kristaliska forma
MX209959B (es) 4-(3-heterociclil-1-benzoil)pirazoles
ID17053A (id) Derivat-derivat 2-(2-okso-etiliden)-imidazolidin-4-on
PT907650E (pt) N-¬4-(heteroarilmetil)fenil|heteroarilaminasc
DK1261585T3 (da) Substituerede indol-Mannichbaser
PT1119430E (pt) Fresa
ID23287A (id) Trisiklik tersubstitusi
NO20020030L (no) Krystallinske 1-metylkarbapenemforbindelser
EE05547B1 (et) Kristalliline efavirens
ID23219A (id) Trisiklik tersubstitusi
DE69714228D1 (de) Kristalline metallophosphate
DE59905139D1 (de) Strukturelement
FI980222A0 (fi) Stycke av isoleringsaemne med en genomgaoende primaerstroemledning
DE19983677T1 (de) Wickelvorrichtung
PT1102747E (pt) Formas cristalinas do osanetant
NO961034L (no) Krystallinske metallofosfater
FI19992282A (fi) Kelauskone
DE69907561D1 (de) Titanatverbindungen
FI980044A0 (fi) Foerfarande foer behandling av en fiberbana
DE59911610D1 (de) Substituierte benzoylcyclohexandione
ATE303996T1 (de) Substituierte acylaminophenyl-uracile
DE59912188D1 (de) Substituierte phenyluracile
ATE272624T1 (de) Substituierte 4-(3-alkenyl-benzoyl)-pyrazole
ATA149998A (de) Ladenbeschlag
FR2787432B1 (fr) Decapsuleur